The conversation discusses a patent filed by Shiseido for cloning Dermal Papilla (DP) cells to treat hair loss. The method involves using viral vectors to maintain the cells' growth-inducing properties, differing from Replicel's approach with DermalSheathCup (DSC) cells.
Shiseido's S-DSChair regenerative treatment in Japan focuses on improving existing hair by thickening miniaturized follicles, not creating new ones. There is limited patient feedback and long-term data available.